Monopar director plans sale of 8,180 shares

Monopar Therapeutics (MNPR) director Kim Tsuchimoto filed a Rule 144 notice to sell up to 8,180 shares of Monopar common stock.

Rhea-AI Filing Summary

Monopar Therapeutics (MNPR) director Kim Tsuchimoto filed a Rule 144 notice to sell up to 8,180 shares of Monopar common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 08/26/2026 and over the next three months via exercise of stock options for cash.

The filing lists an aggregate market value for the planned sale of $906,507.60. Monopar common shares outstanding are reported as 6,712,172, providing context for the relative size of this planned insider sale.

Key Figures

Shares to be sold: 8,180 shares Aggregate market value: $906,507.60 Shares outstanding: 6,712,172 shares +2 more

5 metrics

Shares to be sold 8,180 shares Common stock covered by the Rule 144 notice

Aggregate market value $906,507.60 Value of the 8,180 shares to be sold

Shares outstanding 6,712,172 shares Monopar common shares outstanding referenced in the filing

Approximate sale date 08/26/2026 Approximate date of sale for the covered shares

Shares to be sold acquisition method Exercise of stock options Method by which the securities to be sold were and will be received

Key Terms

Rule 144, aggregate market value, Exercise of Stock Options, NASDAQ

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

aggregate market value financial

"8180 | 906507.60 | 6712172 | 08/26/2026 | NASDAQ"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Exercise of Stock Options financial

"Common | 08/26/2026 | Exercise of Stock Options | Issuer"

NASDAQ market

"6712172 | 08/26/2026 | NASDAQ"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing by MNPR’s Kim Tsuchimoto disclose?

The filing states that Kim Tsuchimoto, a director of Monopar Therapeutics (MNPR), plans to sell up to 8,180 common shares under Rule 144, through Morgan Stanley Smith Barney LLC, with sales tied to the exercise of stock options for cash over the next three months.

How many MNPR shares are planned to be sold and what is their value?

The notice covers up to 8,180 shares of Monopar Therapeutics common stock with an aggregate market value of $906,507.60, as disclosed in the Form 144 filing.

What is the approximate sale date for the MNPR shares in this Form 144?

The Form 144 lists an approximate sale date of 08/26/2026 for the Monopar Therapeutics (MNPR) shares to be sold, with activity expected over the following three months.

How will Kim Tsuchimoto acquire the MNPR shares to be sold?

According to the filing, the securities to be sold were and will be received upon the exercise of stock options. The dates of acquisition and payment were and will be the dates of exercise and sale.

How many Monopar Therapeutics (MNPR) shares are outstanding in this filing?

The Form 144 reports that Monopar Therapeutics has 6,712,172 common shares outstanding, providing context for the size of the planned 8,180-share sale.

On which exchange will the MNPR shares be sold under this Form 144?

The filing indicates that the Monopar Therapeutics (MNPR) common shares covered by this Form 144 are to be sold on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 04:18 PM EDT Accepted by SEC EDGAR 08/26/2026 - 04:18 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001333516
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MONOPAR THERAPEUTICS INC.
SEC File Number	001-39070
Address of Issuer	1000 Skokie Blvd., Suite 350 Wilmette ILLINOIS 60091
Phone	847-388-0349
Name of Person for Whose Account the Securities are To Be Sold	KIM TSUCHIMOTO
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	8180	906507.60	6712172	08/26/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/26/2026	Exercise of Stock Options	Issuer			8180	08/26/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	08/26/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/27/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kim Tsuchimoto
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)